Gaspard Gerschenfeld1, Ioan-Paul Muresan1, Raphael Blanc2, Michael Obadia3, Marie Abrivard2, Michel Piotin2, Sonia Alamowitch4. 1. Service de Neurologie et d'Urgences Neurovasculaires, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, Paris, France. 2. Service de Neuroradiologie Interventionnelle, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France. 3. Service de Neurologie, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France. 4. Service de Neurologie et d'Urgences Neurovasculaires, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, Paris, France4Université Pierre et Marie Curie, INSERM, Système Immunitaire, Neuroinflammation et Maladies Neurodégénératives, Hôpital Saint-Antoine, Paris, France.
Abstract
Importance: Intravenous thrombolysis (IVT) followed by mechanical thrombectomy (MT) is recommended to treat acute ischemic stroke (AIS) with a large vessel occlusion (LVO). Most hospitals do not have on-site MT facilities, and most patients need to be transferred secondarily after IVT (drip and ship), which may have an effect on the neurologic outcome. Objective: To compare the functional independence at 3 months between patients treated under the drip-and-ship paradigm and those treated on site (mothership). Design, Setting, and Participants: This study used a prospectively gathered registry of patients with AIS to select patients admitted through the Saint-Antoine and Tenon (drip and ship) or the Fondation Rothschild (mothership) hospitals from January 1, 2013, through April 30, 2016. The study included patients older than 18 years treated with bridging therapy for AIS with LVO of the anterior circulation. Among the 159 patients who received MT at the mothership, 100 had been transferred after IVT from the drip-and-ship hospitals and 59 had received IVT on site. Main Outcomes and Measures: The main outcome was 3-month functional independence (modified Rankin scale score ≤2). Both groups were compared using a multivariate linear model, including variables that were significantly different in the 2 groups. Results: During the study period, 497 patients were hospitalized at the drip-and-ship and mothership hospitals for an AIS eligible to reperfusion therapy; 11 patients had a basilar artery occlusion and were excluded, leaving 100 patients in the drip-and-ship group (mean age, 73 years; age range, 60-81 years; 57 men [57.0%]) and 59 in the mothership group (mean age, 70 years; age range, 58-82 years; 29 men [49.2%]). The proportion of patients with a favorable neurologic outcome at 3 months was similar in both groups (drip and ship, 61 [61.0%]; mothership, 30 [50.8%]; P = .26), even after adjusting the analysis for the baseline National Institutes of Health Stroke Scale score, diffusion-weighted imaging Alberta Stroke Program Early Computed Tomography Score, and general anesthesia (P = .82). Patients had less severe conditions in the drip-and-ship group (median baseline National Institutes of Health Stroke Scale score, 15 vs 17 [P = .03]; median diffusion-weighted imaging Alberta Stroke Program Early Computed Tomography Score, 7.5 vs 7 [P = .05]). Process times were longer in the drip-and-ship group (onset-to-needle time, 150 vs 135 minutes; onset-to-puncture time, 248 vs 189 minutes; and onset-to-recanalization time, 297 vs 240 minutes; P < .001). Both groups were similar in terms of substantial recanalization (Thrombolysis in Cerebral Ischemia scores 2B to 3; drip and ship, 84 [84.0%]; mothership, 47 [79.7%]; P = .49) and symptomatic hemorrhagic transformation (drip and ship, 2 [2.0%]; mothership, 2 [3.4%]; P = .63). Conclusions and Relevance: This study found that patients treated under the drip-and-ship paradigm also benefit from bridging therapy, with no statistically significant difference compared with those treated directly in a comprehensive stroke center.
Importance: Intravenous thrombolysis (IVT) followed by mechanical thrombectomy (MT) is recommended to treat acute ischemic stroke (AIS) with a large vessel occlusion (LVO). Most hospitals do not have on-site MT facilities, and most patients need to be transferred secondarily after IVT (drip and ship), which may have an effect on the neurologic outcome. Objective: To compare the functional independence at 3 months between patients treated under the drip-and-ship paradigm and those treated on site (mothership). Design, Setting, and Participants: This study used a prospectively gathered registry of patients with AIS to select patients admitted through the Saint-Antoine and Tenon (drip and ship) or the Fondation Rothschild (mothership) hospitals from January 1, 2013, through April 30, 2016. The study included patients older than 18 years treated with bridging therapy for AIS with LVO of the anterior circulation. Among the 159 patients who received MT at the mothership, 100 had been transferred after IVT from the drip-and-ship hospitals and 59 had received IVT on site. Main Outcomes and Measures: The main outcome was 3-month functional independence (modified Rankin scale score ≤2). Both groups were compared using a multivariate linear model, including variables that were significantly different in the 2 groups. Results: During the study period, 497 patients were hospitalized at the drip-and-ship and mothership hospitals for an AIS eligible to reperfusion therapy; 11 patients had a basilar artery occlusion and were excluded, leaving 100 patients in the drip-and-ship group (mean age, 73 years; age range, 60-81 years; 57 men [57.0%]) and 59 in the mothership group (mean age, 70 years; age range, 58-82 years; 29 men [49.2%]). The proportion of patients with a favorable neurologic outcome at 3 months was similar in both groups (drip and ship, 61 [61.0%]; mothership, 30 [50.8%]; P = .26), even after adjusting the analysis for the baseline National Institutes of Health Stroke Scale score, diffusion-weighted imaging Alberta Stroke Program Early Computed Tomography Score, and general anesthesia (P = .82). Patients had less severe conditions in the drip-and-ship group (median baseline National Institutes of Health Stroke Scale score, 15 vs 17 [P = .03]; median diffusion-weighted imaging Alberta Stroke Program Early Computed Tomography Score, 7.5 vs 7 [P = .05]). Process times were longer in the drip-and-ship group (onset-to-needle time, 150 vs 135 minutes; onset-to-puncture time, 248 vs 189 minutes; and onset-to-recanalization time, 297 vs 240 minutes; P < .001). Both groups were similar in terms of substantial recanalization (Thrombolysis in Cerebral Ischemia scores 2B to 3; drip and ship, 84 [84.0%]; mothership, 47 [79.7%]; P = .49) and symptomatic hemorrhagic transformation (drip and ship, 2 [2.0%]; mothership, 2 [3.4%]; P = .63). Conclusions and Relevance: This study found that patients treated under the drip-and-ship paradigm also benefit from bridging therapy, with no statistically significant difference compared with those treated directly in a comprehensive stroke center.
Authors: Alexander Kunz; Martin Ebinger; Frederik Geisler; Michal Rozanski; Carolin Waldschmidt; Joachim E Weber; Matthias Wendt; Benjamin Winter; Katja Zieschang; Jochen B Fiebach; Kersten Villringer; Hebun Erdur; Jan F Scheitz; Serdar Tütüncü; Kerstin Bollweg; Ulrike Grittner; Sabina Kaczmarek; Matthias Endres; Christian H Nolte; Heinrich J Audebert Journal: Lancet Neurol Date: 2016-07-16 Impact factor: 44.182
Authors: Jeffrey L Saver; Mayank Goyal; Alain Bonafe; Hans-Christoph Diener; Elad I Levy; Vitor M Pereira; Gregory W Albers; Christophe Cognard; David J Cohen; Werner Hacke; Olav Jansen; Tudor G Jovin; Heinrich P Mattle; Raul G Nogueira; Adnan H Siddiqui; Dileep R Yavagal; Blaise W Baxter; Thomas G Devlin; Demetrius K Lopes; Vivek K Reddy; Richard du Mesnil de Rochemont; Oliver C Singer; Reza Jahan Journal: N Engl J Med Date: 2015-04-17 Impact factor: 91.245
Authors: Kevin N Sheth; Eric E Smith; Maria V Grau-Sepulveda; Dawn Kleindorfer; Gregg C Fonarow; Lee H Schwamm Journal: Stroke Date: 2015-02-11 Impact factor: 7.914
Authors: Sheryl Martin-Schild; Miriam M Morales; Aslam M Khaja; Andrew D Barreto; Hen Hallevi; Anitha Abraham; M Rick Sline; Elizabeth Jones; James C Grotta; Sean I Savitz Journal: J Emerg Med Date: 2009-03-09 Impact factor: 1.484
Authors: Chelsea S Kidwell; Reza Jahan; Jeffrey Gornbein; Jeffry R Alger; Val Nenov; Zahra Ajani; Lei Feng; Brett C Meyer; Scott Olson; Lee H Schwamm; Albert J Yoo; Randolph S Marshall; Philip M Meyers; Dileep R Yavagal; Max Wintermark; Judy Guzy; Sidney Starkman; Jeffrey L Saver Journal: N Engl J Med Date: 2013-02-08 Impact factor: 91.245
Authors: Yaqian Xu; Neal S Parikh; Boshen Jiao; Joshua Z Willey; Amelia K Boehme; Mitchell S V Elkind Journal: Stroke Date: 2019-04 Impact factor: 7.914
Authors: Susmita Chennareddy; Roshini Kalagara; Colton Smith; Stavros Matsoukas; Abhiraj Bhimani; John Liang; Steven Shapiro; Reade De Leacy; Maxim Mokin; Johanna T Fifi; J Mocco; Christopher P Kellner Journal: BMC Emerg Med Date: 2022-06-16
Authors: Neal S Parikh; Abhinaba Chatterjee; Iván Díaz; Ankur Pandya; Alexander E Merkler; Gino Gialdini; Benjamin R Kummer; Saad A Mir; Michael P Lerario; Matthew E Fink; Babak B Navi; Hooman Kamel Journal: Stroke Date: 2018-01-17 Impact factor: 7.914
Authors: Ronen R Leker; Jose E Cohen; David Tanne; David Orion; Gregory Telman; Guy Raphaeli; Jacob Amsalem; Jonathan Y Streifler; Hen Hallevi; Pavel Gavriliuc; Natan M Bornstein; Anat Horev; Nour Eddine Yaghmour Journal: Interv Neurol Date: 2018-07-04